Edition:
United Kingdom

People: Pfizer Inc (PFE.N)

PFE.N on New York Stock Exchange

42.82USD
22 Jul 2019
Change (% chg)

$0.05 (+0.12%)
Prev Close
$42.77
Open
$42.85
Day's High
$43.01
Day's Low
$42.55
Volume
3,251,622
Avg. Vol
6,542,494
52-wk High
$46.46
52-wk Low
$37.14

Bourla, Albert 

Mr. Albert Bourla is Chief Executive Officer, Director of Pfizer Inc. He has been served as Chief Operating Officer of Pfizer from January 2018 to December 2018; Group President, Pfizer Innovative Health from June 2016 until December 2017; Group President, Global Innovative Pharma Business of Pfizer from February 2016 until June 2016 (responsible for Vaccines, Oncology and Consumer Healthcare since 2014). President and General Manager of Established Products Business Unit of Pfizer from 2010 until 2013. Area President Europe, Africa, Asia and Pacific of Pfizer Animal Health from 2009 until 2010. Area President Europe, Africa and Middle East of Pfizer Animal Health from 2005 until 2009. Since joining Pfizer in 1993, Dr. Bourla has served in various leadership positions with increasing responsibility within Pfizer’s former Animal Health and global commercial organizations.Board member of Pharmaceutical Research and Manufacturers of America (PhRMA). Board member of the Pfizer Foundation, which promotes access to quality healthcare. Member of the Board of the Partnership for New York City and Catalyst, a global non-profit organization accelerating progress for the advancement of women in leadership.

Basic Compensation

Total Annual Compensation, USD 2,933,000
Restricted Stock Award, USD 2,592,080
Long-Term Incentive Plans, USD --
All Other, USD 4,329,480
Fiscal Year Total, USD 9,854,560

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised 20,000 101,074.00
Name Fiscal Year Total

Ian Read

19,549,200

Albert Bourla

9,854,560

Frank D'Amelio

7,139,830

Mikael Dolsten

7,070,200

Michael Goettler

--

Angela Hwang

--
As Of  31 Dec 2018